Skip to main content
RECCE PHARMACEUTICALS LTD logo

RECCE PHARMACEUTICALS LTD — Investor Relations & Filings

Ticker · RCE ISIN · AU000000RCE5 LEI · 549300TKQWXKEHP10T28 ASX Manufacturing
Open in API
Filings indexed 685 across all filing types
Latest filing 2025-05-19 Major Shareholding Noti…
Country AU Australia
Listing ASX RCE

About RECCE PHARMACEUTICALS LTD

https://www.recce.com.au

Recce Pharmaceuticals Ltd is dedicated to the development and commercialization of a new class of synthetic anti-infectives designed to address the global challenge of antimicrobial resistance. The company's lead compound, RECCE® 327, is a broad-spectrum synthetic antibiotic engineered with a unique mechanism of action to combat hyper-mutating bacteria, including both Gram-positive and Gram-negative species. This technology is specifically formulated to maintain efficacy over repeated use, targeting critical medical needs such as sepsis, burn wound infections, and urinary tract infections. By utilizing a proprietary synthetic polymer-based platform, the company aims to disrupt bacterial cellular processes in a manner that prevents the development of resistance, providing a potential solution for multi-drug resistant pathogens.

Recent filings

Filing Released Lang Actions
Change in substantial holding 2 pages 145.0KB
Major Shareholding Notification Classification · 100% confidence The document is a Form 604 under the Corporations Act 2001 Section 671B, titled 'Notice of Change of Interests of Substantial Holder.' It details changes in voting power and relevant interests of a substantial shareholder (FIL Limited and its entities) in Recce Pharmaceuticals Ltd. The form includes dates of changes, number of shares, and voting power percentages. This type of filing is a notification of changes in significant share ownership levels, which matches the definition of 'Major Shareholding Notification' (MRQ). The document length is 3725 characters, which is typical for such notices. There is no indication that this is a full financial report or an announcement of a report publication, so it is not RPA or RNS. Therefore, the correct classification is MRQ with high confidence.
2025-05-19 English
Application for quotation of securities - RCE 6 pages 18.4KB
Share Issue/Capital Change Classification · 95% confidence The document is titled 'Appendix 2A - Application for quotation of securities' and is an announcement from RECCE PHARMACEUTICALS LTD regarding the application for quotation of newly issued securities on the ASX. It details the number and type of securities to be quoted, issue dates, and references previous announcements (Appendix 3B). The document is a formal application for listing new shares on the exchange, not a financial report, earnings release, or management discussion. It is a regulatory announcement related to capital markets activity but specifically about the quotation of securities rather than the issuance itself or a capital raising update. According to the filing definitions, Appendix 2A filings are applications for quotation of securities and fall under the category of Share Issue/Capital Change announcements. The document length is 5529 characters, which is sufficient to contain substantive details of the quotation application, not just a brief notice. Therefore, the best fitting classification is 'SHA' (Share Issue/Capital Change).
2025-05-15 English
Results of Entitlement Offer 3 pages 279.2KB
Capital/Financing Update Classification · 95% confidence The document is an ASX announcement detailing the results of an entitlement offer and shortfall notice, including amounts raised, dates, and use of funds. It focuses on capital raising activities, specifically a share entitlement offer and placement, with no financial statements or detailed financial performance analysis. The content is about fundraising and capital structure changes rather than a full financial report or earnings release. Therefore, it fits the category of Capital/Financing Update (CAP). The document length is over 6,000 characters and contains substantive information about the capital raise, not just a brief notice or report publication announcement.
2025-05-15 English
Change of Director's Interest Notices 18 pages 1.6MB
Director's Dealing Classification · 100% confidence The document is titled 'Appendix 3Y Change of Director’s Interest Notice' and references ASX listing rule 3.19A.2 and section 205G of the Corporations Act. It details changes in securities holdings by company directors, including number of shares held before and after the change, dates of changes, and nature of transactions. The document is a formal notification of personal share transactions by company directors. This matches the definition of 'Director's Dealing' filings, which report personal share transactions by company directors and executives (insider trades). The document is not a full financial report, earnings release, or management report, nor is it an announcement of a report publication. Therefore, the correct classification is DIRS (Director's Dealing). The document length and detail support a high confidence score.
2025-05-15 English
Canadian R&D Rebate Received 2 pages 212.8KB
Regulatory Filings Classification · 95% confidence The document is an ASX announcement from Recce Pharmaceuticals Limited regarding the receipt of a Canadian Scientific Research & Experimental Development (SR&ED) rebate. It discusses the cash receipt amount, the nature of the rebate, and some background on the company's R&D activities. The document is relatively short (3063 characters) and does not contain any financial statements, detailed financial performance data, or comprehensive report content. It is an announcement of a specific financial event (receipt of a government rebate) rather than a full report or detailed financial disclosure. Therefore, it fits best into the category of a Regulatory Filing (RNS), which is a general regulatory announcement that does not fit into more specific categories like Annual Report or Earnings Release.
2025-05-04 English
Extension of Entitlement Offer Closing Date 2 pages 221.6KB
Capital/Financing Update Classification · 95% confidence The document is an ASX announcement regarding the extension of the closing date for a pro-rata non-renounceable entitlement offer, which is a capital raising activity. It provides details about the offer, revised timetable, and instructions for shareholders. There are no financial statements or detailed financial analysis present, and the document is relatively short (4428 characters). This fits the category of a Capital/Financing Update rather than a full financial report or other types of filings.
2025-04-29 English

Browse filings by year

12 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.